PVLA
Palvella Therapeutics
PVLA
PVLA
66 hedge funds and large institutions have $130M invested in Palvella Therapeutics in 2017 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.02% less ownership
Funds ownership: 0.65% → 0.64% (-0.02%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $95K
Holders
66
Holding in Top 10
1
Calls
–
Puts
$95K
Top Buyers
1 | +$1.62M | |
2 | +$1.24M | |
3 | +$1.19M | |
4 |
Cerity Partners
New York
|
+$923K |
5 |
![]()
JPMorgan Chase & Co
New York
|
+$600K |
Top Sellers
1 | -$3.95M | |
2 | -$2.91M | |
3 | -$940K | |
4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$712K |
5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$576K |